Amicus Therapeutics — Q3 2019 Earnings Presentation
23 slides from Amicus Therapeutics's earnings presentation, Nov 14, 2019
Slide 1: 3Q19 Financial Results Conference Call & Webcast
3Q19 Financial Results Conference Call & Webcast November 11, 2019
Slide 2: Forward-Looking Statements
Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica
Slide 3: A Leading Fully-Integrated, Global Rare Disease Biotechnology Company
Introduction 3 A Leading Fully-Integrated, Global Rare Disease Biotechnology Company Gene Therapy World Class PLATFORM BIOLOGICS Protein Engineering Capabilities & Glycobiology AT-GAA Global Footprint Phase 3 in Robust R&D in 27 Countries Pompe Disease Engine Nearly 50+ Lysosomal GLOBAL Disorders an
Slide 4: Key Takeaways for 3Q19 Results
Introduction 4 Key Takeaways for 3Q19 Results Today’s Conference Call and Recent Analyst Day Highlight our Success and Outlook Across our Science, Clinical, Regulatory and Commercial Efforts Galafold Continues Amicus Financial AT-GAA for Pompe Portfolio of Gene Strong Launch Outlook Strengthened Adv
Slide 5: Financial Summary
Financial Summary “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 6: 3Q19 Select Financial Results
Financial Summary 6 3Q19 Select Financial Results 3Q19 Revenue of $48.8M Primarily from Global Galafold Sales Sept. 30, 2019 (in thousands, except per share data) Sept. 30, 2018 Product Revenue 48,768 20,596 Cost of Goods Sold 5,596 4,310 R&D Expense1 58,892 138,227 SG&A Expense 39,680 31,867 Change
Slide 7: Cash Runway Now Well into 1H2022
Financial Summary 7 Cash Runway Now Well into 1H2022 (2.5+ years) Fully Funded Through Major Milestones in Portfolio and Continued Global Growth $420M+ Well into Cash 2.5+ Years Cash Runway 1H2022 YE2019
Slide 8: Financial Summary & Guidance
Financial Summary 8 Financial Summary & Guidance Strong Balance Sheet with $514M+ Cash at 9/30/19 – Cash Runway Well into 1H2022 FINANCIAL POSITION Cash $514M Cash Runway1 Well Into 1H2022 Debt2 $152.8M CAPITALIZATION Shares Outstanding 254,772,163 FINANCIAL GUIDANCE FY19 Galafold Revenue Guidance $
Slide 9: Financial Outlook: Key Takeaways
Financial Summary 9 Financial Outlook: Key Takeaways • Company now fully funded through major milestones in portfolio and continued global growth • Cumulative Galafold projected revenues of $1B+ in 2020-2022 offset significant majority of company spend/investments • Achieved through OpEx savings, Ca
Slide 10: Galafold Global Launch
Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 11: Galafold: Precision Medicine for Fabry Disease
Galafold: Precision Medicine for Fabry Disease 11 Galafold Snapshot (as of September 30, 2019) Galafold is the Cornerstone of Amicus’ Success. It is an Orally Delivered Small Molecule Precision Medicine with a Unique Mechanism of Action for Fabry Patients with Amenable Variants that Replaces the Nee
Slide 12: Galafold Global Launch Momentum
Galafold: Precision Medicine for Fabry Disease 12 Galafold Global Launch Momentum (as of September 30, 2019) Global Commercial Metrics Continue to be Very Strong with >90% Compliance and Adherence, 30% Global Market Share of Treated Amenable Patients and Continued Broad Market Access 3Q19 Strength C
Slide 13: Galafold Success and FY19 Revenue Guidance
Galafold: Precision Medicine for Fabry Disease 13 Galafold Success and FY19 Galafold Revenue Guidance Strong Q3 Performance of $48.8M Gives Confidence in Upwardly Revised Guidance of $170M- $180M. We Expect to Fall in the Midpoint of this Revised Guidance, Inclusive of FX $170M - $180M $48.8M $44.1M
Slide 14: Galafold Growth Trajectory
Galafold: Precision Medicine for Fabry Disease 14 Galafold Growth Trajectory Galafold is on Track to Generate $1B+ in Projected Cumulative Revenues from 2020-2022 and is on an Anticipated Path to $500M+ in Annual Sales in 2023 and $1B+ Annual Sales at Peak $1B $500M+ Annual Revenue $1B Projected Cum
Slide 15: Program Updates
Program Updates “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 16: AT-GAA: Updates & Key Takeaways
AT-GAA for Pompe Disease 16 AT-GAA: Updates & Key Takeaways • PROPEL pivotal study expected to over-enroll (~120 Patients) by YE2019 • Pediatric study underway • Amicus natural history data (POM-002) generally AT-GAA for Pompe consistent with declines in 6MWT in published Advances Toward literature
Slide 17: Gene Therapy: Updates & Key Takeaways
Gene Therapy Portfolio 17 Gene Therapy: Updates & Key Takeaways • CLN6 Phase 2 interim data shows profound impact with potential to become first ever approved gene therapy for fatal brain disease in children • Additional patients to be dosed in Phase 2 study of CLN3 (largest cause of childhood neuro
Slide 18: Closing Remarks
Closing Remarks “We are business led and science driven” - Amicus Belief Statement
Slide 19: 2019 Key Strategic Priorities
Closing Remarks 19 2019 Key Strategic Priorities 1 Nearly double annual revenue for Galafold® (guidance $170M-$180M) Complete enrollment in AT-GAA Pivotal Study (PROPEL) and 2 report additional Phase 1/2 data Report additional 2-year clinical results in CLN6-Batten disease and 3 complete enrollment
Slide 20: Our Passion for Making a Difference Unites Us
Closing Remarks 20 Our Passion for Making a Difference Unites Us Amicus is Now at a Major Inflection Point and Positioned to Create Significant Shareholder Value Ahead while Advancing our Mission for Patients
Slide 21: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement
Slide 22: Appendix
Appendix
Slide 23: Reconciliation
Appendix Reconciliation Amicus Therapeutics, Inc. (in thousands) Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Total operating expenses - as reported $ 100,477 $ 172,467 $ 326,940 $ 307,835 GAAP Research and development: Share-based compensation 3,106 2,905 12,